Publications
Therapies With No Compromise
Poster presented at ESMO TAT 2023 Congress, 6-8 March 2023, Paris
RS-0139, a novel tumor-targeted delivery of docetaxel by SagittaTM
Poster presented at ESMO 2022 Congress, 9-13 September 2022, Paris
Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel by SagittaTM
